湖南南新制药股份有限公司 审计报告 大华审字【2025】0011000458 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) 多可使用手段 "打一事"或理人 "就要是主通到该III的服务是否由具有效能的可售的系列用具、 您可使用手机 "打一流进入 "红吸会计师存业线 - 瑞德运营（https://acc.min.com.cn） - 亚搏体育 京25/F9H20SE 湖南南新制药股份有限公司 审计报告及财务报表 (2024 年 1 月 1 日至 2024 年 12 月 31 日止 ） | 글 | 录 | 页 次 | | --- | --- | --- | | 审计报告 | | 1-7 | | 已审财务报表 | | | | 合并资产负债表 | | 1-2 | | 合并利润表 | | 3 | | 合并现金流量表 | | 4 | | 合并股东权益变动表 | | 5-6 | | 母公司资产负债表 | | 7-8 | | 母公司利润表 | | 9 | | 母公司现金流量表 | | 10 | | 母公司 ...

（二）募集资金本报告期使用金额及期末余额情况 截至 2024 年 12 月 31 日，公司累计使用募集资金 847,535,759.69 元（包含暂时用 于补充流动资金的募集资金 100,000,000.00 元），收到的银行存款利息、理财收益扣 除银行手续费等的净额为 51,001,268.12 元，现金管理余额 0 元，募集资金专户实际余 额 338,747,808.43 元。 明细见下表： 西部证券股份有限公司 关于湖南南新制药股份有限公司 2024年度募集资金存放与使用情况的专项核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南南新制 药股份有限公司（以下简称"南新制药"或"公司"）首次公开发行股票并在科创 板上市的保荐人，根据《证券发行上市保荐业务管理办法》《科创板上市公司持续监 管办法（试行）》《上海证券交易所科创板股票上市规则（2025年4月修订）》《上 市公司监管指引第2号——上市公司募集资金管理和使用的监管要求（2022年修订）》 以及《上海证券交易所科创板上市公司自律监管指引第1号——规范运作（2023年12 月修订）》等有关规定，对南新制药2024年度募集资金存放 ...

湖南南新制药股份有限公司 审计报告 大华审字【2025】0011012678 号 大华会计师事务所(特殊普通合伙) DaHuaCertifiedPublicAccountants (SpecialGeneralPartnership) 意可使用手机"打手了"或进入"注册会计师行业统一直营销售（http://acc.mof.gov.cn/）"进行 板 :编码:京256GM55 湖南南新制药股份有限公司 审计报告及财务报表 (2023 年 1 月 1 日至 2023 年 12 月 31 日止 ) | | 目录 | 页次 | | --- | --- | --- | | 审计报告 | | 1-6 | | 已审财务报表 | | | | 合并资产负债表 | | 1-2 | | 合并利润表 | | 3 | | 合并现金流量表 | | 4 | | 合并股东权益变动表 | | 5-6 | | 母公司资产负债表 | | 7-8 | | 母公司利润表 | | 9 | | 母公司现金流量表 | | 10 | | 母公司股东权益变动表 | | 11-12 | | 财务报表附注 | | 1-87 | 大學会計師事法所 大华会计师事务所 ...

线玩使用手机 智能 才能赚钱 - 能赚到手机现场直播免费注册送在线体育投注网址备用用 _ 湖南南新制药股份有限公司 湖南南新制药股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字【2025】0011000120 号 大华会计师事务所(特殊普通合伙) DaHua Certified Public Accountants (Special General Partnership ) 控股股东及其他关联方资金占用情况的专项说明 (截止 2024 年 12 月 31 日) 资 金 占 用 情 况 的 专 项 说 明 录 页 次 (UV) 1 控股股东及其他关联方资金占用情况的专项 í 1-2 说明 if 湖南南新制药股份有限公司 2024 年度非经营 性资金占用及其他关联资金往来情况汇总表 大學分子向大法所 大华会计师事务所 (结砖普通合伙) 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [1 电话: 86 (10) 5835 0011 传真: 86 (10) 5835 控 股 股 东 及 其 他 关 联 方 大华核字【2025】0011000120 号 湖南南新制药股份有限公司全体股东: ...

经核查公司独立董事丁方飞、沈云樵、聂如琼的兼职、任职情况以及 其签署的独立性自查情况报告，上述人员除在公司担任独立董事外，不存 在在公司任职以及在公司主要股东单位任职的情形，与公司以及主要股东 之间不存在利害关系、重大业务往来或其他可能妨碍其进行独立客观判断 的关系。因此，董事会认为公司独立董事符合《上市公司独立董事管理办 法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 中对独立董事独立性的相关要求。 2025 年 4 月 30 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》、上海 证券交易所《上海证券交易所科创板股票上市规则》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》等法律、行政法规及规 范性文件的相关要求，湖南南新制药股份有限公司（以下简称"公司"） 董事会就公司独立董事丁方飞、沈云樵、聂如琼的独立性情况进行评估并 出具如下专项意见： 湖南南新制药股份有限公司董事会 关于独立董事独立性评估的专项意见 湖南南新制药股份有限公司董事会 ...

Financial Performance - The company achieved operating revenue of 215.33 million yuan, a decrease of 58.09% compared to the same period last year[3]. - The total profit for the period was 12.80 million yuan, down 55.29% year-on-year[3]. - The net profit attributable to shareholders was 10.17 million yuan, a decline of 64.19% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 9.67 million yuan, a decrease of 71.99% year-on-year[3]. - The basic earnings per share were CNY 0.0372, down 64.06% from CNY 0.1035 in the same period last year[19]. - The company’s total assets decreased by 10.26% to CNY 1.54 billion compared to the end of the previous year[18]. - The company reported a net loss of CNY 156,247,362.39, an improvement from a loss of CNY 166,420,045.60 in the previous period[157]. - The company’s net profit for the first half of 2024 was CNY 2,011,132.20, a decrease from CNY 12,146,692.38 in the same period of 2023, representing a decline of approximately 83.5%[167]. Sales and Marketing Strategies - The company adjusted and optimized sales strategies, leading to a reduction in sales prices for some core products, which impacted revenue and gross margin[3]. - The company adjusted sales strategies, leading to a decrease in sales prices for core products, which negatively impacted revenue and gross margin[72]. - The average price reduction for drugs involved in the national centralized procurement has exceeded 50%, significantly impacting the sales revenue of related products[68]. - The company is focusing on maintaining its market share by adjusting sales strategies and optimizing pricing for core products[64]. Research and Development - Research and development expenses accounted for 14.78% of operating revenue, an increase of 4.66 percentage points year-on-year[19]. - The company has 20 new products in development, including 7 innovative drug projects and 12 generic drug projects[26]. - The company is committed to an innovation-driven strategy, increasing R&D investment, and has made significant progress in multiple research projects[35]. - The company has established a complete innovative drug R&D platform covering all stages from target analysis to clinical research, enhancing efficiency in drug discovery[57]. - The company has received 1 new invention patent in the first half of 2024, bringing the total to 28 authorized invention patents[43]. - Total R&D expenditure decreased by 38.79% year-on-year to CNY 31.83 million, primarily due to the completion of production certification and market launch of key projects[46]. - Capitalized R&D investment increased significantly by 505.26% to CNY 17.03 million, reflecting ongoing clinical research progress in the inhalation solution project[48]. Product Development and Innovation - The company has launched the first domestically approved anti-influenza injection, Palivizumab Sodium Injection, which is recommended in various influenza treatment guidelines and has been included in the medical insurance reimbursement list without restrictions for severe cases[28]. - The company is advancing the inhalation solution of Palivizumab, which has completed Phase II clinical trials and is preparing for Phase III trials, aiming to become the world's first nebulized anti-influenza drug[28]. - The company has expanded its product line in the cold and anti-viral sector, including a unique compound ibuprofen tablet and the first pediatric ibuprofen suspension that passed consistency evaluation in China[28]. - The company is enhancing its product offerings in cardiovascular diseases and respiratory diseases, with products like Benazepril Hydrochlorothiazide Tablets and Atorvastatin Calcium Tablets already on the market[29]. - The innovative drug Meifurenone is expected to be a significant breakthrough in the treatment of diabetic nephropathy, currently undergoing Phase II clinical trials[62]. Financial Management and Governance - The board of directors confirmed the authenticity, accuracy, and completeness of the financial report, assuming legal responsibility for any misstatements[3]. - The report is unaudited, and the financial report is guaranteed to be true, accurate, and complete by the responsible persons[6]. - The company has established a comprehensive quality management system and standardized production processes, ensuring all products are produced in-house[31]. - The company has committed to timely reporting any changes in its shareholdings to relevant authorities, ensuring transparency in its operations[102]. - The company guarantees compliance with relevant laws and regulations, ensuring the protection of Nanjing New Pharmaceutical and minority shareholders' interests[106]. Environmental Responsibility - The company has allocated 871,900 CNY for environmental protection efforts during the reporting period[88]. - The company has implemented a mechanism for environmental protection and has not faced any administrative penalties from environmental protection authorities[89]. - The company operates several pollution control facilities, including a comprehensive wastewater treatment facility with a capacity of 600 tons per day, all running normally[93]. - The company has installed online monitoring facilities for various pollutants and has a self-monitoring plan that is regularly updated and publicly disclosed[97]. - The company has implemented carbon reduction measures, focusing on energy conservation and emission reduction in its operations[100]. Shareholder and Dividend Policies - The company plans to distribute profits primarily through cash dividends, with a minimum cash dividend amounting to 10% of the distributable profit for the year[111]. - Over the last three years, the company has cumulatively distributed cash dividends not less than 30% of the average annual distributable profit[111]. - The company committed to distributing at least 80% of profits as cash dividends during profit distribution in a mature development stage without significant capital expenditure[113]. - The company will initiate a share buyback if any false statements or omissions are identified in the prospectus, with a buyback price not lower than the issuance price plus interest[115]. Market Outlook and Future Plans - The management provided a positive outlook for the next quarter, expecting a recovery in revenue growth[179]. - The company plans to expand its market presence and invest in new product development to drive future growth[178]. - The company is considering strategic acquisitions to bolster its market position and diversify its portfolio[178]. - The company has set a target for revenue growth of approximately 5% for the next fiscal year, focusing on market expansion and new product development[180].

Financial Performance - The company's operating revenue for Q1 2025 was ¥40,624,818.43, a decrease of 70.21% compared to ¥111,835,236.68 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥8,028,308.26, representing a decline of 143.66% from a profit of ¥3,766,508.55 in the previous year[4] - The basic and diluted earnings per share were both -¥0.0293, down 143.73% from ¥0.0137 in the same period last year[5] - Net loss for Q1 2025 was ¥8,101,509.23, compared to a net profit of ¥21,423,835.82 in Q1 2024, indicating a significant decline in profitability[22] - Total operating revenue for Q1 2025 was ¥40,624,818.43, a decrease of 70.2% compared to ¥136,374,970.14 in Q1 2024[20] Research and Development - The total R&D investment amounted to ¥24,882,149.56, an increase of 50.68% compared to ¥16,512,853.64 in the previous year[5] - R&D investment accounted for 61.25% of operating revenue, an increase of 49.14 percentage points from 14.77% in the previous year[5] - Research and development expenses for Q1 2025 were ¥10,420,828.81, up 53.5% from ¥6,826,875.34 in Q1 2024, reflecting increased investment in innovation[20] Cash Flow and Liquidity - The net cash flow from operating activities was ¥99,338,104.85, an increase of 169.48% compared to ¥36,863,557.07 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was ¥99,338,104.85, an increase from ¥36,863,557.07 in Q1 2024[24] - Cash inflow from operating activities totaled ¥137,643,739.54 in Q1 2025, compared to ¥129,273,393.29 in Q1 2024, indicating improved cash generation[24] - The company's cash and cash equivalents increased to ¥550,365,903.94 from ¥490,270,275.37, representing an increase of approximately 12.0%[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,212,138,325.93, a decrease of 0.84% from ¥1,222,438,490.23 at the end of the previous year[5] - The equity attributable to shareholders was ¥928,563,813.61, down 0.86% from ¥936,592,121.87 at the end of the previous year[5] - Total liabilities as of the reporting date were ¥341,933,959.48, slightly down from ¥344,132,614.55 in the previous period[20] - The company’s total liabilities increased to ¥1,212,138,325.93, reflecting a stable financial position[16] Market Conditions - The decline in revenue and profit was primarily due to lower market demand for antiviral products and price reductions in response to market competition[8] - The company identified a need to adjust revenue recognition for certain products, resulting in a reduction of ¥24,539,700 in 2023 revenue and an increase in Q1 2024 revenue by the same amount[5] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,843[11] - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, accounting for 28.57% of total shares[12] - The number of shares held in the company's repurchase account is 1,570,586, accounting for 0.57% of the total share capital of 274,400,000 shares[12] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[13] Financial Reporting - The company did not apply new accounting standards starting from 2025[25] - The company’s financial reporting is overseen by Zhang Shixi, Li Liang, and Chen Xiaoning[26]

Financial Performance - The company's operating revenue for the third quarter was ¥35,783,445.19, a decrease of 25.93% compared to the same period last year, and a year-to-date decline of 55.32% to ¥251,110,585.69[3] - The net profit attributable to shareholders was -¥67,388,600.14 for the quarter, with a year-to-date loss of -¥57,215,916.93, representing an increase of 8,895.45% compared to the previous year[3] - Total operating revenue for the first three quarters of 2024 was CNY 251,110,585.69, a decrease of 55.32% compared to CNY 562,058,852.86 in the same period of 2023[18] - Net profit for the first three quarters of 2024 was a loss of CNY 65,925,432.36, compared to a profit of CNY 998,459.62 in the same period of 2023[20] - The basic and diluted earnings per share for the first three quarters of 2024 were both CNY -0.2089, compared to CNY 0.0024 in 2023[20] Research and Development - Research and development (R&D) expenses totaled ¥25,419,547.01 for the quarter, an increase of 49.13%, and accounted for 71.04% of operating revenue, up 35.75 percentage points[4] - The company is increasing its investment in R&D, particularly in the clinical trials for the Palivizumab inhalation solution project[8] - The company reported a significant increase in research and development expenses, totaling CNY 26,325,369.38 for the first three quarters of 2024, compared to CNY 63,925,857.68 in 2023[19] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥30,109,281.80, down 66.01% compared to the previous year[3] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 30,109,281.80, a decrease of 66.06% from CNY 88,584,510.48 in 2023[21] - The ending balance of cash and cash equivalents was $388,506,660.17, down from $561,729,383.46 at the beginning of the period[22] - The company reported a net decrease in cash and cash equivalents of -$173,222,723.29 during the period[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,069[10] - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, representing 28.57% of total shares[10] Liabilities and Equity - The company's total liabilities amounted to CNY 158,904,683.58, while total equity was CNY 1,209,656,281.13 as of the reporting date[18] - The total equity attributable to shareholders of the parent company was CNY 1,236,281,830.33, a decrease from CNY 1,303,495,883.51 in the previous year[18] Cost Management - Total operating costs for the first three quarters of 2024 were CNY 221,340,831.77, down from CNY 508,120,982.75 in 2023, reflecting a reduction of 56.47%[19] - The company reported a significant reduction in sales expenses, which were CNY 64,474,681.29 for the first three quarters of 2024, down from CNY 341,793,551.23 in 2023[19] Asset Changes - The total assets at the end of the reporting period were ¥1,368,560,964.71, a decrease of 20.40% from the previous year-end[4] - Total current assets decreased from ¥1,271,857,772.05 as of December 31, 2023, to ¥911,150,884.10 as of September 30, 2024, a decline of approximately 28.37%[13] - Cash and cash equivalents decreased from ¥665,760,897.54 to ¥389,076,108.51, a reduction of about 41.5%[13] - Accounts receivable decreased from ¥520,668,671.48 to ¥427,921,860.87, a decline of approximately 17.8%[13] - Inventory increased from ¥30,365,696.49 to ¥67,051,501.23, an increase of about 120.8%[13] - Total current liabilities decreased from ¥428,035,296.07 to ¥153,760,240.79, a reduction of about 64.0%[14] - Short-term borrowings decreased significantly from ¥322,950,113.81 to ¥65,050,555.56, a decline of approximately 79.9%[14]

Financial Performance - The company achieved operating revenue of CNY 720.06 million in 2023, an increase of 3.04% compared to CNY 698.83 million in 2022[22]. - The net profit attributable to shareholders was a loss of CNY 10.87 million in 2023, improving from a loss of CNY 78.83 million in 2022[22]. - The net cash flow from operating activities was CNY 215.23 million, a significant recovery from a negative cash flow of CNY -160.09 million in 2022[22]. - The basic earnings per share for 2023 was -CNY 0.0396, an improvement from -CNY 0.2873 in 2022[23]. - The quarterly revenue for Q4 2023 was CNY 158.00 million, with a net profit loss of CNY -11.52 million, indicating fluctuations in performance throughout the year[26]. - Operating costs rose to 111.79 million yuan, reflecting a 12.55% increase year-on-year, resulting in a gross margin of 84.47%, down 1.31 percentage points[81]. - The company reported a net profit attributable to shareholders of -10.87 million yuan, with a net profit excluding non-recurring items of -3.54 million yuan[79]. - The revenue from antiviral drugs reached CNY 64,282.65 million, with a gross margin of 90.23%, reflecting a year-on-year revenue increase of 39.27%[111]. Research and Development - Research and development expenses accounted for 12.94% of operating revenue, up from 9.22% in the previous year, indicating increased investment in innovation[23]. - The company has 22 new products in development, including 7 innovative drug projects and 13 generic drug projects[33]. - The company has filed for 3 new invention patents and received 3 new authorized patents during the reporting period, totaling 35 authorized patents[33]. - The company has increased its R&D investment by 44.57% compared to the previous year, primarily due to increased clinical research costs for the drug Meifurenketone and improvements in the processes for Palivizumab Sodium Injection and Lactic Acid Ciprofloxacin Sodium Injection[57]. - The total R&D expenditure for the year is approximately ¥93.18 million, with a significant increase in capitalized R&D investment by 190.93% to ¥18.32 million[59]. - The company has developed core technologies in drug design and discovery, which are essential for new drug development[50]. - The company is conducting Phase II clinical trials for a new innovative drug targeting diabetic nephropathy, which is expected to be a significant breakthrough in treatment[33]. - The company is conducting Phase II clinical trials for a modified new drug, an inhalation solution of peramivir, which aims to be the world's first nebulized inhalation antiviral drug[45]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a governance structure that includes a board of directors, supervisory board, and senior management, ensuring checks and balances[137]. - The board consists of 7 members, including 3 independent directors, ensuring a fair and transparent election process[138]. - The company has implemented a comprehensive internal control system to maintain effective oversight of its management team[141]. - The company adheres to strict information disclosure practices, ensuring transparency and equal access to information for all shareholders[141]. - The company held four shareholder meetings during the reporting period, all resolutions were approved without any rejections[146]. - The company has not reported any changes in shareholding for its directors and senior management during the reporting period[148]. - The company has maintained its internal control audit institution for 2023[146]. Market and Sales Strategy - The company is expanding its sales channels and adjusting its sales model to achieve steady revenue growth[34]. - The company has established a marketing network covering over 30 provinces, focusing on expanding the OTC market and enhancing brand awareness[36]. - The company is focusing on optimizing the evaluation and approval process for radioactive drugs, which are crucial for treating serious diseases[49]. - The company is actively planning new product launches to create new revenue and profit growth points[35]. - The company is focusing on expanding its product line in the antiviral and infectious disease treatment sectors, with a strong emphasis on innovative drugs[66]. - The company is accelerating the layout of its product lines in cardiovascular diseases, respiratory diseases, and antipyretic analgesics, with existing products including Benazepril Hydrochlorothiazide tablets and Atorvastatin Calcium tablets[68]. Risk Factors - The company emphasizes the importance of risk factors in its forward-looking statements, urging investors to be cautious[6]. - The company faces risks related to the lengthy and costly new drug approval process, with uncertainty regarding the success of its clinical trials and regulatory approvals for its pipeline products[73]. - The company’s core product, Palivizumab Sodium Injection, is at risk of being replicated by competitors, which could lead to increased market competition and potential price declines[75]. - The company faced risks related to centralized procurement policies that could significantly affect sales revenue and volumes of its main products[77]. Compliance and Regulatory Matters - The company received administrative regulatory measures from the China Securities Regulatory Commission on April 26, 2023, requiring corrections to prior accounting errors[168]. - The company disclosed corrected annual and quarterly reports for 2020 and 2021 on June 28, 2023, confirming the rectification of accounting errors[169]. - The company submitted a rectification report to the Shanghai Stock Exchange on July 5, 2023, in response to a regulatory warning received on June 6, 2023[170]. - The company has been actively addressing regulatory measures from the Hunan Securities Regulatory Bureau as part of its compliance efforts[173]. Employee and Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 4.8608 million RMB[164]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 2.6229 million RMB[164]. - The company has a competitive compensation policy, providing various insurance and benefits to employees[187]. - The company employed a total of 360 staff, with 50 in the parent company and 310 in major subsidiaries[186]. - A total of 14 external training sessions and 344 internal training sessions were conducted in 2023 to enhance employee skills and teamwork[189].

Financial Performance - The company reported a profit distribution plan for 2024, proposing no cash dividends, no bonus shares, and no capital reserve conversion into shares [5]. - The company has not achieved profitability since its listing [3]. - The company reported a revenue of CNY 263.28 million for 2024, a decrease of 63.44% compared to the previous year [24]. - The net profit attributable to shareholders was a loss of CNY 356.90 million, significantly worsening from a profit of CNY 3.75 million in 2023 [24]. - Basic and diluted earnings per share for 2024 were both CNY -1.3007, reflecting a substantial decline from CNY 0.0137 in 2023 [22]. - The net cash flow from operating activities was CNY 1.39 million, a decline of 99.35% compared to the previous year [23]. - Total assets decreased by 28.90% to CNY 1.22 billion at the end of 2024, down from CNY 1.72 billion in 2023 [23]. - The weighted average return on equity was -31.87% for 2024, a significant drop from -0.83% in 2023 [22]. - The gross margin decreased to 54.59%, down 29.89 percentage points year-on-year [86]. - The total profit for the period was -388.64 million yuan, with a net profit attributable to shareholders of -356.90 million yuan [70]. Research and Development - The company’s R&D expenditure accounted for 43.81% of its revenue, an increase of 30.87 percentage points year-on-year [22]. - The company’s R&D investment totaled 115.34 million RMB, accounting for 43.81% of operating revenue, an increase of 30.87 percentage points from the previous year [37]. - The total R&D investment for the year reached ¥115,337,991.94, an increase of 23.77% compared to the previous year [56]. - The company has cumulatively obtained 23 authorized patents and 4 software copyrights as of December 31, 2024 [37]. - The company is focusing on continuous cost reduction and efficiency improvement while streamlining its organizational structure [37]. - The company is conducting Phase II clinical trials for the acid-suppressing drug, with smooth participant enrollment, aiming to delay kidney fibrosis and improve kidney function in diabetic nephropathy treatment [39]. - The company has established a research and development system combining innovative and generic drugs, with a product lineup of 38 chemical drug varieties and 58 formulation production approvals [49]. - The company has launched the first domestic anti-influenza innovative drug, Palivizumab Sodium Injection, and is conducting Phase III clinical trials for a modified new drug, Palivizumab Inhalation Solution [50]. - The company has successfully developed products like Acetaminophen Mannitol Injection using its soft bag infusion technology, which offers advantages over traditional glass bottle infusions [54]. - The company is actively pursuing a diversified approach to international market expansion, including independent clinical development and licensing out [52]. Market and Competition - The company adjusted its sales strategy and reduced prices for core products due to increased market competition and policy changes [24]. - The company experienced a significant decline in sales due to fewer flu cases in the second, third, and fourth quarters of 2024 [24]. - The company is responding to increased market competition and price pressures due to policy changes and intensified market competition in the pharmaceutical sector [35]. - The company is preparing to submit applications for several generic drugs, including Acetaminophen Mannitol injection [115]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential deals [153]. Governance and Compliance - The audit report issued by Da Hua Certified Public Accountants is a standard unqualified opinion [4]. - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report [3]. - The company has not violated decision-making procedures for external guarantees [7]. - The company has not disclosed any special governance arrangements [8]. - The company has not faced any issues regarding independence from its controlling shareholders [143]. - The company has established a comprehensive internal control system to ensure compliance and enhance operational efficiency [185]. - The company has implemented a strict information disclosure management system to ensure transparency and fairness in communications with investors [142]. - The company has not reported any violations of laws or regulations by its directors or senior management [142]. Environmental and Social Responsibility - The company emphasizes ESG principles in its operations, focusing on climate change, resource management, and social responsibility [188]. - The company invested ¥1,447,300 in environmental protection during the reporting period [191]. - The company has established an environmental protection mechanism and has not experienced any environmental pollution incidents or administrative penalties [192]. - The company has a comprehensive wastewater treatment facility with a processing capacity of 600 tons per day, operational since March 2017 [197]. - The company is committed to reducing pollutant emissions and enhancing energy efficiency through clean production practices [189]. Employee and Management - The company has a total of 366 employees, with 247 in production, 33 in sales, 42 in technology, 10 in finance, and 34 in administration [173]. - The total compensation for key personnel during the reporting period amounted to 519.61 million yuan [147]. - The company has maintained a consistent shareholding structure with no changes in the number of shares held by key personnel throughout the year [147]. - The company is focused on ensuring a smooth transition as key personnel retire and new members are integrated into the team [148]. - The company is committed to adhering to legal retirement age regulations for its employees [148].